Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02886104
Other study ID # E2016026
Secondary ID
Status Recruiting
Phase N/A
First received August 24, 2016
Last updated August 28, 2016
Start date August 2016
Est. completion date July 2026

Study information

Verified date August 2016
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact Meijin Huang, MD,PHD
Phone +8613924073322
Email maymay0129@139.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The surgical and local ablation strategy for the treatment of resectable synchronous and metachronous colorectal liver metastases(CRLM) has not still been defined. The purpose of this study is to compare two treatment strategies in which simultaneous resection of both primary and secondary tumor of synchronous CRLM(SCRLM) and resection of metachronous CRLM(MCRLM) is compared with resection of primary tumor and ablation of secondary tumor in SCRLM and ablation of MCRLM. Endpoints include the rate of severe complications and survival.


Description:

Colorectal cancer(CRC) kills more than 700,000 patients every year, which is nowadays the world's 3rd common and the 4th deadly tumor. About 50% CRC patients will finally develop colorectal liver metastasis (CRLM). Among the CRLM patients, 20-25% of CRC are found with synchronous colorectal liver metastases (SCRLM) at the first visit. Meanwhile, about 20-30% CRC patients suffer by metachronous colorectal liver metastasis (MCRLM) even after radical resection of primary tumor. It is nowadays admitted that the R0 resection of both primary and secondary tumors in SCRLM and R0 resection of MCRLM represents a feasible and potential curative treatment in patients with resectable CRLM(RCRLM). However, the treatment strategy for some RCRLM (tumor number≤3 and tumor size≤3.0cm), such as whether to choose hepatectomy or local ablation, still remains in debate. In primary hepatocellular carcinoma(HCC), local ablation has been proved to has similar curative effect to that of hepatectomy. Compared to hepatectomy, local ablation has less trauma and more rapid recovery and possible lower hospitalization cost. The curative effect of local ablation is mainly influenced by tumor site and tumor size. On the other side, some RCRLM might develop repeat recurrences even after "R0" resection due to the imaging undetectable micro metastasis. Thus, local ablation might be more suitable for some repeat recurrent CRLM. The aim of this study is to compare the efficacy/safety of local ablation with hepatectomy for RCRLM (tumor number≤3, tumor size≤3.0cm), including both SCRLM and MCRLM. Patients are randomized to CRLM resection group and local ablation group. The primary endpoint is overall survival. Secondary endpoints evaluate the rate of patients with at least one severe complication within 30 days after surgery/ablation and long-term clinical outcomes, in particular disease-free survival.


Recruitment information / eligibility

Status Recruiting
Enrollment 548
Est. completion date July 2026
Est. primary completion date July 2021
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. At least one metastatic adenocarcinoma of liver, histologically proven.

2. At least one adenocarcinoma of colon and/or rectum, histologically proven.

3. No local complication at the time of surgery (no occlusion, no sub-occlusion, no massive hemorrhage, no abscesses or local invasion).

4. No extra-hepatic metastasis.

5. Extra-hepatic disease (EHD) suitable for hepatectomy, liver ablation and anesthesia as long as all sites of EHD disease are radically treated.

6. All the primary and secondary tumors which R0 resections are technically possible. (SCRLM: synchronous resection for both primary and secondary tumors, MCRLM: no local recurrence within 6 months after resection of primary tumor)

7. Residual hepatic volume>30%-40%.

8. At least 2-3 hepatic segments remained after hepatectomy (except S1), residual liver with normal portal vein, hepatic artery and biliary duct, at least 1 of hepatic veins (left, middle and right) not invaded.

9. Tumor size =3 cm.

10. Tumor number= 3.

11. Tumors located =1.0 cm of vulnerable structures, e.g. colon, main trunk of portal vein, hepatic artery, hepatic vein and intrahepatic biliary duct.

12. suitable for both hepatectomy and local ablation after multiple disciplinary team(MDT) discussion.

13. Informed written consent.

Exclusion Criteria:

1. Other malignant tumors history.

2. Complications need emergency surgery (occlusion, sub-occlusion, massive hemorrhage and abscesses, et al.).

3. Colorectal or hepatic tumor extension towards abdominal wall and/or adjacent organ making liver R0 resection impossible immediately.

4. Hepatic lesions diagnosed with ultrasound and MRI making complete ablation impossible immediately.

5. = 2 hepatic segments remained after hepatectomy or residual hepatic volume?30%-40%

6. Non resectable lymph node metastasis.

7. American Society of Anesthesiologists(ASA) grading= IV and/or Eastern cooperative oncology group(ECOG) score= 2. (see appendix)

8. EHD is not recommended.

9. Physical or psychological dependence.

10. Pregnant or breast feeding women.

11. Not controlled preoperational infection.

12. Enrolled in other clinical trials within 4 weeks. Other clinical or laboratorial condition not recommended by investigators.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
CRLM resection group
Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
Device:
CRLM ablation group
Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.

Locations

Country Name City State
China The 6th Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong

Sponsors (3)

Lead Sponsor Collaborator
Sixth Affiliated Hospital, Sun Yat-sen University First Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (5)

Bethke A, Kühne K, Platzek I, Stroszczynski C. Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. Cancer Imaging. 2011 Jun 29;11:91-9. doi: 10.1102/1470-7330.2011.0015. — View Citation

Brody H. Colorectal cancer. Nature. 2015 May 14;521(7551):S1. doi: 10.1038/521S1a. — View Citation

Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 2015 Feb;35(2):255-65. doi: 10.1177/0272989X14544749. Epub 2014 Jul 29. — View Citation

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27(22):3677-83. doi: 10.1200/JCO.2008.20.5278. Epub 2009 May 26. — View Citation

Livraghi T. Single HCC smaller than 2 cm: surgery or ablation: interventional oncologist's perspective. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):425-9. doi: 10.1007/s00534-009-0244-x. Epub 2009 Nov 5. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival 3 years Yes
Secondary R0 resection rate in both primary and secondary tumor in CRLM Day of surgery Yes
Secondary Death rate during hospitalization or within 30 days after surgery/ablation 30 days after surgery/ablation Yes
Secondary Rate of patients with at least one postoperative severe complication within 30 days after surgery/ablation 30 days after surgery/ablation Yes
Secondary Disease-free survival and 1, 2 and 3-years disease-free survival rate 1, 2 and 3-years Yes
Secondary Complete ablation rate in CRLM Day of ablation Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02758977 - Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) N/A
Terminated NCT02820194 - A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM) N/A
Completed NCT01457599 - Computertomography-guided Wire Marking of the Liver N/A
Completed NCT02843802 - Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer Phase 1/Phase 2
Not yet recruiting NCT02647047 - Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery N/A
Active, not recruiting NCT01516710 - Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study N/A
Completed NCT02391207 - Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence N/A
Recruiting NCT03889093 - Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System N/A
Completed NCT01423734 - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Completed NCT00199173 - Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only Phase 3